Leadership Transition at CYIOS Corporation
In a significant shift, CYIOS Corporation (OTC: CYIO) recently announced that David Lewis has stepped down from his positions within the company. As part of the transition, he voluntarily returned 16,560 Series D Preferred Shares to CYIOS and canceled all outstanding salary and loan obligations. This strategic decision is set to bolster the company’s financial health, simplify its capital structure, and lay the groundwork for future growth. The company expresses its best wishes to David for his next endeavors.
Enhancing Financial Transparency
CYIOS is actively collaborating with its independent auditor to complete two years of PCAOB-audited financial statements, with the aim of fully completing the 2024 statements. This is a crucial milestone in enhancing transparency and compliance within the organization. Concurrently, CYIOS remains focused on boosting working capital through strategic investment initiatives aimed at alleviating Noir Medical Supplies’ debt obligations, a key priority expected to reach completion by the middle of 2026.
Comments from Leadership
John O’Shea, Chairman and CEO of CYIOS Corporation, expressed his enthusiasm about these developments, stating, “These are meaningful milestones in strengthening CYIOS’ foundation for growth. We remain committed to disciplined financial management, profitable expansion, and delivering long-term value to our shareholders.”
Embracing Artificial Intelligence and SaaS
A key development is CYIOS’s initiative to engage expert advisors in Artificial Intelligence (AI) and Software-as-a-Service (SaaS). This aims to strategically plan CyioIQ, which represents CYIOS’s ambitious AI-Driven Medical Platform. The focus is on defining the platform’s architecture, design, business case, and potential build costs. This initiative is poised to amplify CYIOS’s role in the medical and health supply sector.
Streamlining Operations and Revenue Generation
By implementing AI, CYIOS envisions streamlining operations within Noir Medical Supplies, which could enhance operational efficiency and profitability. Additionally, the integration of AI is expected to unlock potential new revenue avenues through partnerships with third-party distribution agencies in the industry. Details regarding this exciting initiative will be available soon.
About CYIOS Corporation
CYIOS Corporation (OTC: CYIO) operates as a diversified holding company that is committed to building, acquiring, and managing innovative businesses across various sectors, including medical supplies, technology, and fintech. With a focus on its subsidiary Noir Medical Supplies, CYIOS is dedicated to expanding its footprint in the U.S. medical distribution market, emphasizing operational excellence and sustainable profitability.
Contact Information
For further inquiries, please reach out to the Investor Relations team at CYIOS Corporation via email at info@cyioscorporation.com or visit their official website at www.cyioscorporation.com.
Frequently Asked Questions
What changes have occurred in the leadership of CYIOS Corporation?
CYIOS Corporation has announced the resignation of David Lewis, who has returned shares and canceled outstanding obligations, allowing for enhanced financial focus.
How is CYIOS Corporation enhancing its financial transparency?
The company is partnering with independent auditors to complete PCAOB-audited financial statements, which supports transparency and compliance.
What initiatives is CYIOS taking in artificial intelligence?
CYIOS is recruiting AI and SaaS advisors to develop an AI-Driven Medical Platform named CyioIQ, aimed at enhancing operational efficiencies and profitability.
What are the future priorities for CYIOS Corporation?
Key priorities include reducing debt obligations in Noir Medical Supplies and laying a robust foundation for profitable expansion and shareholder value.
Where can I find more information about CYIOS Corporation?
For more details, visit the official website of CYIOS Corporation or contact their Investor Relations team directly.
